Liquidia Corporation (NASDAQ:LQDA) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET

Company Participants

Jason Adair - Senior Vice President, Corporate Development and Strategy

Roger Jeffs - Chief Executive Officer

Dr. Rajeev Saggar - Chief Medical Officer

Rusty Schundler - General Counsel

Mike Kaseta - Chief Financial Officer

Conference Call Participants

Greg Harrison - Bank of America

Serge Belanger - Needham & Company

Matt Kaplan - Ladenburg Thalmann

Julian Harrison - BTIG

Operator

Good morning. And welcome everyone to the Liquidia Corporation Second Quarter 2022 Financial Results and Corporate Update Conference Call. My name is Angela, and I will be your conference operator today. Currently, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for questions. [Operator Instructions]

I would like to remind everyone that the conference call is being recorded. I will now hand the call over to Jason Adair, Senior Vice President, Corporate Development and Strategy.

Jason Adair

Thank you, Angela. It is my pleasure to welcome everyone to Liquidia’s second quarter 2022 financial results and corporate update conference call. Joining the call today are Chief Executive Officer, Roger Jeffs; Chief Medical Officer, Dr. Rajeev Saggar; General Counsel, Rusty Schundler; Chief Financial Officer, Mike Kaseta; and other members of Liquidia management.

Before we begin, please note that today’s conference call will contain forward-looking statements, including those statements regarding future results and forward-looking financial information, as well as the company’s future performance and/or achievements.

These statements are subject to known and unknown risks and uncertainties, which may cause our actual results or performance to be materially different from any future results or performance expressed or implied on this call.

For additional information, including a detailed discussion of our risk factors, please refer to the company documents filed with the Securities and Exchange Commission, which can be accessed on our website.

I would now like to turn the call over to Roger for our prepared remarks, after which he will open up the call for your questions.

Roger Jeffs

Thank you, Jason, and good morning, everyone. Over the last three months, we’ve continued to gain momentum across all areas of the company as we build towards our primary objective of preparing for the potential launch of YUTREPIA, an inhaled dry powder formulations to treprostinil. I’ll share just a few examples of our progress.